<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE ep-patent-document SYSTEM "ep-patent-document-v1-4.dtd">
<ep-patent-document id="EP1438405A1" country="EP" dtd-version="ep-patent-document-v1-4.dtd" doc-number="1438405" date-publ="20040721" file="02779511.1" lang="de" kind="A1" status="n"><SDOBI lang="de"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEE....SK................</B001EP><B003EP>*</B003EP><B005EP>X</B005EP><B007EP>DIM350 (Ver 2.1 Jan 2001) 1100000/0 1710000/0</B007EP></eptags></B000><B100><B110>1438405</B110><B130>A1</B130><B140><date>20040721</date></B140><B190>EP</B190></B100><B200><B210>02779511.1</B210><B220><date>20021025</date></B220><B240><B241><date>20040403</date></B241></B240><B250>De</B250><B251EP>De</B251EP><B260>De</B260></B200><B300><B310>10155280</B310><B320><date>20011026</date></B320><B330><ctry>DE</ctry></B330><B310>10158411</B310><B320><date>20011129</date></B320><B330><ctry>DE</ctry></B330><B310>10160151</B310><B320><date>20011207</date></B320><B330><ctry>DE</ctry></B330><B310>PCT/EP02/00151</B310><B320><date>20020109</date></B320><B330><ctry>WO</ctry></B330><B310>PCT/EP02/00152</B310><B320><date>20020109</date></B320><B330><ctry>WO</ctry></B330><B310>10235620</B310><B320><date>20020802</date></B320><B330><ctry>DE</ctry></B330></B300><B400><B405><date>20040721</date><bnum>200430</bnum></B405><B430><date>20040721</date><bnum>200430</bnum></B430></B400><B500><B510><B516>7</B516><B511> 7C 12N  15/11   A</B511><B512> 7A 61K  31/713  B</B512><B512> 7C 12N  15/88   B</B512><B512> 7A 61P  35/00   B</B512></B510><B540><B541>de</B541><B542>VERWENDUNG EINER DOPPELSTRÄNGIGEN RIBONUKLEINSÄURE ZUR GEZIELTEN HEMMUNG DER EXPRESSION EINES VORGEGEBENEN ZIELGENS</B542><B541>en</B541><B542>USE OF A DOUBLE-STRANDED RIBONUCLEIC ACID FOR SPECIFICALLY INHIBITING THE EXPRESSION OF A GIVEN TARGET GENE</B542><B541>fr</B541><B542>UTILISATION D'UN ACIDE RIBONUCLEIQUE DOUBLE BRIN POUR INHIBER DE MANIERE CIBLEE L'EXPRESSION D'UN GENE CIBLE DETERMINE</B542></B540></B500><B700><B710><B711><snm>Ribopharma AG</snm><iid>03946272</iid><irf>443281EH</irf><adr><str>Fritz-Hornschuch-Strasse 9</str><city>95326 Kulmbach</city><ctry>DE</ctry></adr></B711></B710><B720><B721><snm>LIMMER, Stefan</snm><adr><str>Gutenbergstrasse 9</str><city>95512 Neudrossenfeld</city><ctry>DE</ctry></adr></B721><B721><snm>KREUTZER, Roland</snm><adr><str>Glotzdorf 26</str><city>95466 Weidenberg</city><ctry>DE</ctry></adr></B721><B721><snm>JOHN, Matthias</snm><adr><str>Kapellenstrasse 12</str><city>96103 Hallstadt</city><ctry>DE</ctry></adr></B721></B720><B740><B741><snm>Gassner, Wolfgang, Dr.</snm><iid>00085693</iid><adr><str>Dr. Gassner &amp; PartnerNägelsbachstrasse 49a</str><city>91052 Erlangen</city><ctry>DE</ctry></adr></B741></B740></B700><B800><B840><ctry>AT</ctry><ctry>BE</ctry><ctry>BG</ctry><ctry>CH</ctry><ctry>CY</ctry><ctry>CZ</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>EE</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>IE</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LU</ctry><ctry>MC</ctry><ctry>NL</ctry><ctry>PT</ctry><ctry>SE</ctry><ctry>SK</ctry><ctry>TR</ctry></B840><B844EP><B845EP><ctry>AL</ctry></B845EP><B845EP><ctry>LT</ctry></B845EP><B845EP><ctry>LV</ctry></B845EP><B845EP><ctry>MK</ctry></B845EP><B845EP><ctry>RO</ctry></B845EP><B845EP><ctry>SI</ctry></B845EP></B844EP><B860><B861><dnum><anum>EP2002011969</anum></dnum><date>20021025</date></B861><B862>De</B862></B860><B870><B871><dnum><pnum>WO2003035869</pnum></dnum><date>20030501</date><bnum>200318</bnum></B871></B870></B800></SDOBI></ep-patent-document>
